Vital Breast Cancer Drugs Highlight Funding Ethics (Izindaba)

Vital Breast Cancer Drugs Highlight Funding Ethics (Izindaba)

The ongoing reluctance to proclaim two breast cancer drugs proven to slow early disease progression and save lives for specific indications has frustrated State medical oncologists anxious to thrash out a speedy solution, especially in the Western Cape. They are in urgent talks with resource-constrained Western Cape and national pharmaceutical coding committees, whom they say have quibbled for years, citing drug cost inequities, cost inefficiencies and data paucity on ‘life years’. Widely known as the most prevalent cancer in women nationally, the only available caseload data (National Cancer Registry, 1999) put annual breast cancer diagnoses in South Africa at 6 000, with the lifetime risk for women at 1 in 27.

Vital Breast Cancer Drugs Highlight Funding Ethics (Izindaba)

Vital Breast Cancer Drugs Highlight Funding Ethics (Izindaba) | | 4.5